97278-75-6

Upstream product

• 101386-40-7 (R)-2-[1-Benzyloxycarbonylmethyl-2-oxo-1,4,5,6-tetrahydro-2H-benzo[b]azocin-(3E)-ylideneamino]-4-phenyl-butyric acid ethyl ester 
• 683-18-1 dibutyltin chloride 
• 46460-23-5 ethyl 2-amino-4-phenyl-(2S)-butyrate 
• 97278-73-4 1-<(carbobenzyloxy)methyl>-3,4,5,6-tetrahydro-1-benzazocine-2,3(1H)-dione 
• 97278-72-3 3-azido-3,4,5,6-tetrahydro-1-benzazocin-2(1H)-one 
• 91167-28-1 3-bromo-3,4,5,6-tetrahydro-1-benzazocin-2(1H)-one 
• 22246-75-9 3,4,5,6-tetrahydro-1-benzazocin-2(1H)-one 

Relevant academic research and scientific papers

Certain benzazocinone and benzazoninone derivatives

Variously substituted 1-carboxymethyl-3-(carboxymethylamino)-benzazocin-2-one and benzazonin-2-one derivatives are disclosed as angiotensin converting enzyme inhibitors and anti-hypertensive agents. Synthesis of, pharmaceutical compositions and methods of

Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme

Syntheses of the potent angiotensin converting enzyme inhibitor (3S)-1-(carboxymethyl)-3-[[(1S)-1-carboxy-3-phenylpropyl]amino]-2,3,4,5 -tetrahydro-1H-[1]benzazepin-2-one (CGS 14831) and the related monoester prodrug (17a; CGS 14824A) are described together with preparative details for six- and eight-membered ring analogues. Inhibitory potencies and in vivo biological activity of the compounds are discussed. The data indicate that 17a has a biological profile comparable to that of enalapril.